Showing 7071-7080 of 7635 results for "".
- Modernizing Medicine, Inc. Acquires Aesyntix Health, Inc.https://practicaldermatology.com/news/modernizing-medicine-inc-acquires-aesyntix-health-inc/2459037/Modermizing Medicine, Inc., creator of the Electronic Medical Assistant® (EMA™), completed an acquisition of Aesyntix Health, Inc. on
- FDA Approves Galderma's Soolantra to Treat Rosaceahttps://practicaldermatology.com/news/fda-approves-galdermas-soolantra-for-rosacea/2459038/The FDA approved Galderma’s Soolantra (ivermectin) Cream 1% for the once-daily topical treatment of inflammatory lesions, or bumps and pimples, of rosacea. R Recent studies have further solidified that generally harmless microscopic Demodex mites may also be a culprit. These mites are norma
- Galderma Laboratories Launches First OTC Acne Regimen, Benzac® Acne Solutionshttps://practicaldermatology.com/news/galderma-laboratories-launches-first-otc-acne-regimen-benzac-acne-solutions/2459041/Galderma Laboratories, L.P., maker of Cetaphil®, is launching Benzac® Acne Solutions, its first-ever, over-the-counter (OTC) acne regimen. Benzac treats stubborn acne and prevents new breakouts from forming with salicylic acid, while pharmaceutical grade East Indian Sandalwood Oil calms a
- Provectus Biopharmaceuticals to Meet with FDA on Operational Aspects of PV-10 Phase 3 Melanoma Studyhttps://practicaldermatology.com/news/provectus-biopharmaceuticals-to-meet-with-fda-on-operational-aspects-of-pv-10-phase-3-melanoma-study/2459043/Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT,http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company (“Provectus”), announced today that it will be me
- Pierre Fabre Dermatologie Receives the Prix Galien Award for Pharmaceutical Research for Hemangiolhttps://practicaldermatology.com/news/pierre-fabre-dermatologie-receives-the-prix-galien-award-for-pharmaceutical-research-for-hemangiol/2459047/Pierre Fabre Dermatologie, a subsidiary of Pierre Fabre Dermo-Cosmetics, was distinguished by the Prix Galien award (France) for Hemangiol, an oral pediatric propranolol solution specifically developed for some severe infantile hemangiomas. Hemangiol® was successively approved by Americ
- Sienna Labs Obtains Fifth Patent Relating to Use of Plasmonic Nanoparticles in Treatment of Sebaceous Glands and Hairhttps://practicaldermatology.com/news/sienna-labs-obtains-fifth-patent-relating-to-use-of-plasmonic-nanoparticles-in-treatment-of-sebaceous-glands-and-hair/2459048/Siienna Labs was issued US Patent No. 8,895,071 covering, among other aspects, methods of using the company's plasmonic nanoparticle platform for localizing thermal damage to sebaceous glands and hair, a key mechanism for their investigational acne treatment and hair removal indications.
- DermSpectra Releases Total Body Digital Skin Imaging Systemhttps://practicaldermatology.com/news/dermspectra-releases-its-total-body-digital-skin-imaging-system/2459052/DermSpectra realease its DermSpectra Total Body Digital Skin Imaging System, which enables physicians to monitor critical skin changes (skin cancers, eczema, lesions, psoriasis, and rashes) over time. The DermSpectra advanced medical technology allows physicians to digitally capture and compare s
- FDA Approves Valeant's Onexton Gel for the Treatment of Acne Vulgarishttps://practicaldermatology.com/news/fda-approves-valeants-onexton-gel-for-the-treatment-of-acne-vulgaris/2459053/The FDA approved Valeant Pharmaceuticals International, Inc.’s Onexton Gel (clindamycin phosphate and benzoyl peroxide) 1.2%/3.75% for the once-daily treatment of comedonal and inflammatory acne in patients 12 and older. "We are very pleased that the FDA has approved this new d
- PV-10 Data Published; Phase 3 Protocol Publishedhttps://practicaldermatology.com/news/20141121-pv-10_data_published_phase_3_protocol_published/2459054/Phase II data for PV-10 (Provectus Biopharmaceuticals, Inc.), presented at scientific meetings this fall, were published in Annals of Surgical Oncology in October. In the 80-subject study, the best overall response rate for target lesions was 51 percent, and the complete response rate was 26 percent
- Gabrielle Rios, Founder of TruInject, Wins Stevie Award for Startupshttps://practicaldermatology.com/news/20141119-gabrielle_rios_founder_of_truinject_wins_stevie_award_for_startups/2459058/Gabrielle Rios, chief executive officer of TruInject Medical Corporation, received the Bronze Award at the 2014 Stevie Awards for Women in Business. The award was presented in the category of Startup of the Year. The Stevie® Awards for Women in Business honors women executives, entrepreneurs, a